Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | DGKA | P23743 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10172806 | 0.94 | NAAA (0.55) | NAAAHTTRAD52NPSR1FAAH | |
| Propionic Acid SCHEMBL27519317 | 0.93 | NAAA (0.56) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL6410095 | 0.92 | NAAA (0.53) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL13331043 | 0.85 | NAAA (0.48) | NAAAHTTAPPDGKAGAA | |
| SCHEMBL17753939 | 0.85 | NAAA (0.46) | NAAARAD52NPSR1FAAHHTR2C | |
| SCHEMBL28245871 | 0.83 | NAAA (0.47) | NAAAHTTAPPDGKAGAA | |
| SCHEMBL50185 | 0.82 | NAAA (0.81) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL6128364 | 0.80 | DGKA (0.65) | NAAARAD52NPSR1FAAHHTR2C | |
| SCHEMBL10267034 | 0.80 | DGKA (0.65) | NAAARAD52NPSR1FAAHHTR2C | |
| SCHEMBL28200825 | 0.80 | HTR2C (0.57) | NAAARAD52NPSR1FAAHHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115157-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12527755-B2 | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240358544-A1 | METHOD OF TREATING VISION LOSS IN A HUMAN SUBJECT WITH PHOTOREACTIVE COMPOUNDS | KIORA PHARMACEUTICALS PTY LTD (AU) | 2024-10-31 | — | — | US | disclosed |
| US-20230357451-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2023-11-09 | — | — | US | disclosed |
| US-11795241-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-3183295-B1 | FRACTIONATED ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230002513-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2023-01-05 | — | — | US | disclosed |
| EP-4083075-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | CyDex Pharmaceuticals, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| US-20220332853-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-10-20 | — | — | US | disclosed |
| US-9200098-B2 | Radiation-sensitive composition and compound | JSR CORPORATION (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9200098-B2 | Radiation-sensitive composition and compound | JSR CORPORATION (JP) | 2015-12-01 | — | — | US | disclosed |
| EP-2883867-A2 | Non-aqueous electrolytic solution, electrochemical element using the same and alkynyl compound used therefor | Ube Industries, Ltd. (JP) | 2015-06-17 | — | — | EP | disclosed |
| EP-2533344-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, ELECTROCHEMICAL ELEMENT USING SAME, AND ALKYNYL COMPOUND USED THEREFOR | Ube Industries, Ltd. (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-20120164582-A1 | RADIATION-SENSITIVE COMPOSITION AND COMPOUND | JSR CORPORATION (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358544-A1 | METHOD OF TREATING VISION LOSS IN A HUMAN SUBJECT WITH PHOTOREACTIVE COMPOUNDS | PDE6C, ALDH1A2, PDE6D | NAAA 1990/4885HTT 1746/4885RAD52 3129/4885 |
| US-20260115157-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | CYP2C8, CYP3A43, SULT2A1 | NAAA 2512/4885HTT 1699/4885RAD52 4390/4885 |
| US-11795241-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | AGPS, DDOST, ALG1 | NAAA 3265/4885HTT 2310/4885RAD52 2912/4885 |
| US-12527755-B2 | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin | TPMT, GSTP1, ALB | NAAA 4043/4885HTT 1300/4885RAD52 4479/4885 |
| US-20220332853-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | DCXR, AGL, OSTC | NAAA 4419/4885HTT 3046/4885RAD52 4080/4885 |
| US-20120164582-A1 | RADIATION-SENSITIVE COMPOSITION AND COMPOUND | RAD51, RER1, ATP6AP1 | NAAA 1947/4885HTT 4841/4885RAD52 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.